Elimination of immune responses to viral vectors
AssigneesLife Sciences Research Partners VZW, Katholieke Universiteit Leuven
InventorJean-Marie Saint-Remy
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from a viral vector antigen and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the prevention and/or suppression of immune responses to viral vectors and in the manufacture of medicaments therefore.
Claims15
A method of suppressing, in a mammalian recipient receiving a viral vector for gene therapy or for gene vaccination which encodes a therapeutic protein, an immune response to a protein encoded by said viral vector, other than the therapeutic protein, comprising the step of administering to said recipient an immunogenic peptide of between 12 and 50 amino acids comprising (i) a T-cell epitope of said protein encoded by said viral vector;
- and (ii) a C-(X)2-[CST] or [CST]-(X)2-C motif, wherein said C-(X)2-[CST] or [CST]-(X)2-C motif is immediately adjacent to said T-cell epitope, or is separated from said T-cell by a linker of at most 7 amino acids.
Dependencies are inferred from the claim text.